Latest Healthcare News

Pro Medicus Limited has reported a robust half-year financial performance for the period ending December 31, 2024, with net profit soaring 42.7% and an increased interim dividend declared.

Micro-X Limited has initiated a $2.7 million retail entitlement offer as part of a broader $6 million capital raising, supporting its strategic pivot towards medical imaging technologies and strengthening its balance sheet.

ASX Limited has reported a robust first half of FY25 with record operating revenue and a near 10% rise in underlying net profit, underpinned by strong growth across key business segments and a strategic focus on technology modernization.

Telix Pharmaceuticals has gained UK MHRA approval for Illuccix, its advanced prostate cancer PET imaging agent, promising to alleviate supply shortages and improve diagnostic accuracy across the UK.

Artrya has secured a pivotal three-year commercial contract with Sonic Healthcare Australia to deploy its AI-driven Salix Coronary Anatomy platform across over 125 radiology centres, marking a significant step in commercialising its coronary artery disease diagnostic technology.

Echo IQ has secured a $1.26 million refund under the Australian Government's R&D Tax Incentive, reinforcing its commitment to AI-driven solutions for structural heart disease detection.

Sigma Healthcare has completed its acquisition of Chemist Warehouse, issuing new shares and cash to former shareholders and appointing a refreshed board to steer the merged entity forward.

Vitura Health Limited has acquired Candor Medical, a leading Australian medicinal cannabis clinic, for $5.9 million, significantly boosting its digital health platform and patient base.

Vitura Health has raised $5.1 million from prominent investor Professor Khalil Shahin, marking a significant step towards acquiring Candor Medical and accelerating its digital health expansion.

EMVision Medical Devices has secured US ethics approval for its pivotal multi-centre trial of the EMVision emu™ brain scanner, paving the way for a March 2025 trial start aimed at FDA clearance.

Arena REIT has delivered a strong half-year 2025 performance, with significant profit growth driven by strategic acquisitions and development completions, while reaffirming its distribution guidance and sustainability commitments.

Arena REIT delivered a robust HY2025 performance with statutory net profit soaring 87%, underpinned by strategic acquisitions and development completions. The REIT reaffirmed its FY2025 distribution guidance, signaling confidence in sustained growth amid a strong social infrastructure portfolio.